Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Finerenone Versus Alternate-Day Spironolactone in Patients With Heart Failure and Diabetic Kidney Disease at High Risk for Hyperkalemia: The SAFE-K Randomized Trial

NCT07523867 is registered in ClinicalTrials.gov with Hospital de Messejana Dr. Carlos Alberto Studart Gomes as lead sponsor.

NCT NCT07523867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Finerenone Versus Alternate-Day Spironolactone in Patients With Heart Failure and Diabetic Kidney Disease at High Risk for Hyperkalemia: The SAFE-K Randomized Trial
Lead sponsor
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
November 30, 2026
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease, heart failure, hyperkalemia